Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/QLT Visudyne Expanded Indications Cover Up To 250,000 Patients

Executive Summary

The approval of Novartis/QLT's Visudyne (verteporfin) for use in pathologic myopia and presumed ocular histoplasmosis could double the labeled patient population for the ophthalmic agent.
Advertisement

Related Content

Novartis, CMS Continue To Talk On Visudyne Macular Degeneration Coverage
Novartis/QLT Visudyne Medicare Coverage Expansion Awaits More Data
Novartis/QLT Visudyne Medicare Coverage Expansion Awaits More Data
Ciba Vision/QLT Visudyne Will Have Average Annual Cost of $4,175/Patient
Ciba Vision/QLT Visudyne Will Have Average Annual Cost of $4,175/Patient
Advertisement
UsernamePublicRestriction

Register

PS038411

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel